PLN and diabetic cardiomyopathy: In case of diabetic injury, breviscapine may have a protective effect on diabetic cardiomyopathy by decreasing the expression of protein kinase C (PKC) and phospholamban (PLB), as well as increasing the expression of protein phosphatase inhibitor-1 (PPI-1), Ca(2+)-ATPase (SERCA-2), and ryanodine receptor (RyR) (Wang et al., 2010).